Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate genetic biomarkers of long-term response. Therefore...

ver descrição completa

Detalhes bibliográficos
Autores: Zapata-Cobo, P, Salvador-Martin, S, Velasco, M, Palomino, LM, Clemente, S, Segarra, O, Moreno-Alvarez, A, Fernandez-Lorenzo, A, Perez-Moneo, B, Montraveta, M, Sanchez, C, Tolin, M, Loverdos, I, Fobelo, MJ, Navas-Lopez, VM, Magallares, L, Garcia-Romero, R, Sanchez-Hernandez, JG, Rodriguez, A, Bossacoma, F, Balboa, MJ, Salcedo, E, Sanjurjo-Saez, M, Lopez-Fernandez, LA
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p3694
Acesso em linha:https://i3pt.portalinvestigacion.com/publicaciones/3694
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165352409&doi=10.1016%2fj.phrs.2023.106859&partnerID=40&md5=781006b641acd4882ca92935a2f2954b
Access Level:acceso abierto
Palavra-chave:Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Pharmacogenetics
Infliximab
Adalimumab
Polymorphism
Pediatric
id ES_4952a2fd99b4ff76de683abd4cb5511b
oai_identifier_str oai:i3pt.fundanetsuite.com:p3694
network_acronym_str ES
network_name_str España
repository_id_str
spelling Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in childrenZapata-Cobo, PSalvador-Martin, SVelasco, MPalomino, LMClemente, SSegarra, OMoreno-Alvarez, AFernandez-Lorenzo, APerez-Moneo, BMontraveta, MSanchez, CTolin, MLoverdos, IFobelo, MJNavas-Lopez, VMMagallares, LGarcia-Romero, RSanchez-Hernandez, JGRodriguez, ABossacoma, FBalboa, MJSalcedo, ESanjurjo-Saez, MLopez-Fernandez, LAInflammatory bowel diseaseCrohn's diseaseUlcerative colitisPharmacogeneticsInfliximabAdalimumabPolymorphismPediatricFew genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate genetic biomarkers of long-term response. Therefore, the aim of the study was to analyze the usefulness of biomarkers of response to anti-TNFs in pediatric IBD (pIBD) as long-term biomarkers and to find differences by type of IBD and type of anti-TNF drug. The study population comprised 340 children diagnosed with IBD who were treated with infliximab or adalimumab. Genotyping of 9 selected SNPs for their association with early response and/or immunogenicity to anti-TNFs was performed using real-time PCR. Variants C rs10508884 (CXCL12), A rs2241880 (ATG16L1), and T rs6100556 (PHACTR3) (p value 0.049; p value 0.03; p value 0.031) were associated with worse long-term response to anti-TNFs in pIBD. DNA variants specific to disease type and anti-TNF type were identified in the pediatric population. Genotyping of these genetic variants before initiation of anti-TNFs would enable, if validated in a prospective cohort, the identification of pediatric patients who are long-term responders to this therapy.ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/3694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165352409&doi=10.1016%2fj.phrs.2023.106859&partnerID=40&md5=781006b641acd4882ca92935a2f2954bPHARMACOLOGICAL RESEARCHISSN: 10436618ISSNe: 10961186reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p36942026-06-21T15:30:37Z
dc.title.none.fl_str_mv Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
title Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
spellingShingle Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Zapata-Cobo, P
Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Pharmacogenetics
Infliximab
Adalimumab
Polymorphism
Pediatric
title_short Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
title_full Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
title_fullStr Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
title_full_unstemmed Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
title_sort Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
dc.creator.none.fl_str_mv Zapata-Cobo, P
Salvador-Martin, S
Velasco, M
Palomino, LM
Clemente, S
Segarra, O
Moreno-Alvarez, A
Fernandez-Lorenzo, A
Perez-Moneo, B
Montraveta, M
Sanchez, C
Tolin, M
Loverdos, I
Fobelo, MJ
Navas-Lopez, VM
Magallares, L
Garcia-Romero, R
Sanchez-Hernandez, JG
Rodriguez, A
Bossacoma, F
Balboa, MJ
Salcedo, E
Sanjurjo-Saez, M
Lopez-Fernandez, LA
author Zapata-Cobo, P
author_facet Zapata-Cobo, P
Salvador-Martin, S
Velasco, M
Palomino, LM
Clemente, S
Segarra, O
Moreno-Alvarez, A
Fernandez-Lorenzo, A
Perez-Moneo, B
Montraveta, M
Sanchez, C
Tolin, M
Loverdos, I
Fobelo, MJ
Navas-Lopez, VM
Magallares, L
Garcia-Romero, R
Sanchez-Hernandez, JG
Rodriguez, A
Bossacoma, F
Balboa, MJ
Salcedo, E
Sanjurjo-Saez, M
Lopez-Fernandez, LA
author_role author
author2 Salvador-Martin, S
Velasco, M
Palomino, LM
Clemente, S
Segarra, O
Moreno-Alvarez, A
Fernandez-Lorenzo, A
Perez-Moneo, B
Montraveta, M
Sanchez, C
Tolin, M
Loverdos, I
Fobelo, MJ
Navas-Lopez, VM
Magallares, L
Garcia-Romero, R
Sanchez-Hernandez, JG
Rodriguez, A
Bossacoma, F
Balboa, MJ
Salcedo, E
Sanjurjo-Saez, M
Lopez-Fernandez, LA
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Pharmacogenetics
Infliximab
Adalimumab
Polymorphism
Pediatric
topic Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Pharmacogenetics
Infliximab
Adalimumab
Polymorphism
Pediatric
description Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate genetic biomarkers of long-term response. Therefore, the aim of the study was to analyze the usefulness of biomarkers of response to anti-TNFs in pediatric IBD (pIBD) as long-term biomarkers and to find differences by type of IBD and type of anti-TNF drug. The study population comprised 340 children diagnosed with IBD who were treated with infliximab or adalimumab. Genotyping of 9 selected SNPs for their association with early response and/or immunogenicity to anti-TNFs was performed using real-time PCR. Variants C rs10508884 (CXCL12), A rs2241880 (ATG16L1), and T rs6100556 (PHACTR3) (p value 0.049; p value 0.03; p value 0.031) were associated with worse long-term response to anti-TNFs in pIBD. DNA variants specific to disease type and anti-TNF type were identified in the pediatric population. Genotyping of these genetic variants before initiation of anti-TNFs would enable, if validated in a prospective cohort, the identification of pediatric patients who are long-term responders to this therapy.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/3694
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165352409&doi=10.1016%2fj.phrs.2023.106859&partnerID=40&md5=781006b641acd4882ca92935a2f2954b
url https://i3pt.portalinvestigacion.com/publicaciones/3694
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165352409&doi=10.1016%2fj.phrs.2023.106859&partnerID=40&md5=781006b641acd4882ca92935a2f2954b
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
publisher.none.fl_str_mv ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
dc.source.none.fl_str_mv PHARMACOLOGICAL RESEARCH
ISSN: 10436618
ISSNe: 10961186
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407416726061056
score 15,811543

Registos relacionados